Evidence map›Paper›PMID 42144562›Full record

ArticleClinical and translational science2026

Ecopipam, a Dopamine D1 Receptor Antagonist: Pharmacokinetics, Mass Balance, and Metabolism in Healthy Volunteers.

Virginia D Schmith, Stephen English, Angela Dymond, Catherine Holdsworth, Ruth Stow, Emma Holbrook, Joy Schleyer, Stephen P Wanaski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Cardiovascular pharmacology of dopaminergic agents in humans: a review.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Virginia D SchmithSchmith PK/PD Consulting, LLC and Syntegrity Quantitative Clinical Pharmacology Collaborative, Cocoa Beach, Florida, USA.ORCID 0000-0003-2841-2384
Stephen EnglishPharmaron, Germantown, Maryland, USA.
Angela DymondLabcorp, Leeds/Harrogate, UK.
Catherine HoldsworthLabcorp, Leeds/Harrogate, UK.
Ruth StowLabcorp, Leeds/Harrogate, UK.
Emma HolbrookLabcorp, Leeds/Harrogate, UK.
Joy SchleyerEmalex Biosciences, Inc., Chicago, Illinois, USA.
Stephen P WanaskiParagon Biosciences, LLC, Chicago, Illinois, USA.

Funding

Emalex Biosciences
6 · The paper itself

Abstract

Ecopipam is a dopamine-1 (D1) receptor antagonist in development for Tourette syndrome. In vitro data showed that ecopipam is metabolized to ecopipam glucuronide through uridine diphosphate-glucuronosyltransferase 1A9 and to EBS-101-40853 (previously called N-desmethylecopipam or SCH 40853) through cytochrome P450 3A4. This open-label, non-randomized, mass balance study investigated metabolism and elimination pathways of ecopipam. A single oral dose of ecopipam 179.2 mg containing 88.5 μCi (3.27 MBq) of [

Indexed as

Dopamine AntagonistsPiperazinesReceptors, Dopamine D1Administration, OralAdultBenzazepinesFecesHealthy VolunteersHumansMaleYoung AdultBenzazepinesDopamine AntagonistsecopipamPiperazinesReceptors, Dopamine D1dopamine antagonistsdrug metabolismecopipamglucuronidationunidentified metabolites

Identifiers

PMID42144562
PMCPMC13180694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.